Published in Scand J Urol Nephrol on January 01, 2007
Immunogenicity of botulinum toxins. J Neural Transm (Vienna) (2012) 0.99
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med (2013) 0.89
Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity. J Exerc Rehabil (2016) 0.81
New insights into the pharmacology of the bladder. Curr Opin Urol (2008) 0.81
Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol (2012) 0.79
The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA. Urol Ann (2015) 0.78
Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol (2016) 0.78
Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Int J MS Care (2013) 0.78
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. Int Braz J Urol (2015) 0.77
Intravesical oxybutynin in the pediatric neurogenic bladder. Nat Rev Urol (2009) 0.76
The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol (2013) 0.75
Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis. Can Urol Assoc J (2014) 0.75
The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol (2016) 0.75
Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. Int Neurourol J (2017) 0.75
Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2016) 0.75
Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport(®)) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity? Toxins (Basel) (2015) 0.75
Survey of spinal cord injury-induced neurogenic bladder studies using the Web of Science. Neural Regen Res (2012) 0.75
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins (Basel) (2016) 0.75
Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity. World J Urol (2015) 0.75
Use of botulinum toxin for voiding dysfunction. Transl Androl Urol (2017) 0.75
Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. Curr Urol Rep (2017) 0.75
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Robot-assisted radical cystectomy with intracorporeal urinary diversion in patients with transitional cell carcinoma of the bladder. Eur Urol (2011) 1.80
A randomized, controlled trial of transanal irrigation versus conservative bowel management in spinal cord-injured patients. Gastroenterology (2006) 1.79
A novel product for intermittent catheterisation: its impact on compliance with daily life--international multicentre study. Eur Urol (2006) 1.48
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler (2010) 1.46
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clin Pharmacol Ther (2006) 1.25
Multipotent progenitor cells from the adult human brain: neurophysiological differentiation to mature neurons. Brain (2005) 1.22
Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol (2008) 1.12
Neurogenesis in the adult spinal cord in an experimental model of multiple sclerosis. Eur J Neurosci (2006) 1.11
TLR activation induces TNF-alpha production from adult neural stem/progenitor cells. J Immunol (2009) 1.05
Effects of functional electrical stimulation training for six months on body composition and spasticity in motor complete tetraplegic spinal cord-injured individuals. J Rehabil Med (2002) 1.01
Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler (2013) 0.96
Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. Phytomedicine (2008) 0.92
Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion. J Neurotrauma (2006) 0.91
Nitric oxide exposure diverts neural stem cell fate from neurogenesis towards astrogliogenesis. Stem Cells (2006) 0.89
The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PLoS One (2011) 0.86
Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol (2003) 0.86
A European approach to clinical investigator training. Front Pharmacol (2013) 0.85
Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One (2013) 0.85
Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology (2002) 0.85
Pain in a Swedish spinal cord injury population. Clin Rehabil (2003) 0.85
Measuring seating pressure, area, and asymmetry in persons with spinal cord injury. Eur Spine J (2003) 0.83
Distribution and characterization of progenitor cells within the human filum terminale. PLoS One (2011) 0.83
Nitric oxide as a marker for evaluation of treatment effect of cyclosporine A in patients with bladder pain syndrome/interstitial cystitis type 3C. Scand J Urol (2013) 0.81
Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. Br J Clin Pharmacol (2011) 0.81
Proliferation, migration and differentiation of ependymal region neural progenitor cells in the brainstem after hypoglossal nerve avulsion. Restor Neurol Neurosci (2011) 0.80
Sitting balance and effects of kayak training in paraplegics. J Rehabil Med (2004) 0.80
Nitric oxide-induced neuronal to glial lineage fate-change depends on NRSF/REST function in neural progenitor cells. Stem Cells (2014) 0.79
Oxidative stress increases neurogenesis and oligodendrogenesis in adult neural progenitor cells. Stem Cells Dev (2014) 0.79
Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia. Drug Metab Lett (2010) 0.79
FGF1 containing biodegradable device with peripheral nerve grafts induces corticospinal tract regeneration and motor evoked potentials after spinal cord resection. Restor Neurol Neurosci (2012) 0.78
Pain, especially neuropathic pain, in adults with spina bifida, and its relation to age, neurological level, completeness, gender and hydrocephalus. J Rehabil Med (2010) 0.78
Treatment of stress urinary incontinence: recent developments in the role of urethral injection. Urol Res (2003) 0.78
Neural stem/progenitor cells transplanted to the hypoglossal nucleus integrates with the host CNS in adult rats and promotes motor neuron survival. Cell Transplant (2011) 0.78
Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers. Ther Drug Monit (2010) 0.78
Effects of long term NOS inhibition on disease and the immune system in MOG induced EAE. Nitric Oxide (2005) 0.77
Reduced neuronal injury after treatment with NG-nitro-L-arginine methyl ester (L-NAME) or 2-sulfo-phenyl-N-tert-butyl nitrone (S-PBN) following experimental brain contusion. Neurosurgery (2005) 0.77
Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence. Urology (2004) 0.76
Treatment of stress urinary incontinence using a copolymer system: impact on quality of life. BJU Int (2004) 0.75
Levels of nitric oxide metabolites in cerebrospinal fluid in cluster headache. Cephalalgia (2010) 0.75
[Research without ethical approval occurs--often negligence behind. Review of Karolinska Institute's publications 2006]. Lakartidningen (2009) 0.75
[Neurological issues common during internship. A questionnaire study as a basis for continuous development of neurology teaching]. Lakartidningen (2011) 0.75
Preserved somatosensory conduction in a patient with complete cervical spinal cord injury. J Rehabil Med (2015) 0.75
Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells. Biochem Biophys Res Commun (2013) 0.75
High incidence of falls and fall-related injuries in wheelchair users with spinal cord injury: A prospective study of risk indicators. J Rehabil Med (2017) 0.75
Incidence, aetiology and injury characteristics of traumatic spinal cord injury in Stockholm, Sweden: A prospective, population-based update. J Rehabil Med (2017) 0.75
[In Process Citation]. Lakartidningen (2015) 0.75
Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer. Ther Drug Monit (2016) 0.75
[EU strikes hard against clinical research--an EU project ECRIN builds bridges for clinical trials]. Lakartidningen (2010) 0.75
[Final reply: drug companies must be allowed to make profit]. Lakartidningen (2006) 0.75
Comparison of uptake mechanisms for anthracyclines in human leukemic cells. Curr Drug Deliv (2013) 0.75